Completed PHASE1 INTERVENTIONAL NCT00498745

Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects

A Single Dose Bioavailability Study of 2 New Formulations of HKI-272 (240 mg) Compared With a Reference Capsule and an Oral Solution in Healthy Adult Subjects

Sponsor: Puma Biotechnology, Inc.

Conditions Healthy

Interventions neratinib

Updated 5 times since 2017 Last updated: May 10, 2012 Started: Jul 31, 2007 Completion: Sep 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by Puma Biotechnology, Inc. and has accumulated 5 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Puma Biotechnology, Inc.

Data source: Puma Biotechnology, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Antonio, United States